Alcon has officially announced the U.S. commercial launch of Tryptyr (acoltremon ophthalmic solution) 0.003%, following its FDA approval in May. Eye care professionals (ECPs) across the country can now prescribe Tryptyr to patients suffering from dry eye disease (DED). The therapy represents a first-in-class advancement in the treatment of DED, targeting both the signs and symptoms of this prevalent condition..

爱尔康在五月获得FDA批准后，正式宣布了0.003%浓度的Tryptyr（乙酰色胺眼药水）在美国市场的商业上市。全国各地的眼科护理专业人士（ECPs）现在可以为干眼症（DED）患者开具Tryptyr处方。这种疗法代表了治疗干眼症这一普遍病症的首创新进展，针对其症状和体征双管齐下。

Overview of Tryptyr’s Mechanism of Action and Clinical Impact

Tryptyr的作用机制和临床影响概述

Tryptyr is a TRPM8 receptor agonist, acting as a neuromodulator that stimulates corneal sensory nerves to rapidly boost natural tear production. Clinical trials demonstrated that Tryptyr produced a statistically significant increase in natural tear production as early as Day 1, providing a fast-acting solution for patients with dry eye symptoms..

Tryptyr是一种TRPM8受体激动剂，作为神经调节剂，刺激角膜感觉神经以快速促进天然泪液的产生。临床试验表明，Tryptyr在第1天就显著增加了天然泪液的产生，为干眼症状患者提供了快速起效的解决方案。

“Tryptyr is highly anticipated in the dry eye disease treatment space as the first neuromodulator eye drop to rapidly increase natural tear production, as early as day one,” said Lisa Praeger, Vice President and General Manager of U.S. Ocular Health Pharmaceutical at Alcon.

“Tryptyr 作为首款神经调节剂滴眼液，能够在第一天就迅速增加自然泪液分泌，因此在干眼症治疗领域备受期待。” 美国爱尔康眼科健康制药副总裁兼总经理丽莎·普雷格表示。

Commercial Strategy and ECP Engagement

商业策略与ECP参与

As part of the launch, Alcon is implementing a comprehensive education and engagement campaign for ECPs, which includes videos and digital tools, an interactive website tailored for professionals, a dedicated patient-facing website, and a national broadcast event featuring expert-led discussions on Tryptyr and its clinical application in dry eye disease..

作为上市的一部分，爱尔康正在为眼科保健专业人士实施一项全面的教育和参与活动，其中包括视频和数字工具、一个专为专业人士设计的互动网站、一个面向患者的专用网站，以及一场由专家主导的全国广播活动，讨论Tryptyr及其在干眼病中的临床应用。

These initiatives aim to inform and equip ECPs with resources to help integrate Tryptyr into their dry eye treatment protocols.

这些举措旨在为眼科护理专业人员提供资源，帮助他们将Tryptyr整合到干眼症治疗方案中。

Access and Affordability Initiatives

获取与可负担性倡议

To support broader patient access, Alcon has introduced a series of access-focused programs, including a ‘First Fill Free’ trial for eligible patients, ongoing copay support for refill prescriptions, and a field-based access management team dedicated to assisting providers with coverage and reimbursement logistics..

为了让更多患者获得药物，爱尔康推出了一系列以获取为重点的计划，包括为符合条件的患者提供“首次免费试用”、持续的处方补充费用支持，以及一支现场访问管理团队，专门帮助供应商处理覆盖范围和报销物流事宜。

According to Alcon, these initiatives are designed to ensure that cost and coverage are not barriers to treatment, particularly during the initial stages of therapy.

根据爱尔康的说法，这些举措旨在确保费用和保险覆盖不会成为治疗的障碍，特别是在治疗的初始阶段。

“As the global eye care leader with a comprehensive portfolio of dry eye products—from over-the-counter offerings to prescription therapies—Alcon is uniquely positioned to deliver this innovation to ECPs and the millions of patients who need dry eye disease relief,” said Praeger.

“作为全球眼科护理的领导者，拥有从非处方产品到处方疗法的全面干眼产品组合，爱尔康在将这一创新带给眼科护理专业人士和数百万需要缓解干眼病症状的患者方面具有独特的优势，”Praeger表示。